Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

BeiGene Snags 8th Approval for PD-1 mAb in China

publication date: Apr 15, 2022

Beijing’s BeiGene reported China approved use of its PD-1 antibody as a second line treatment for esophageal squamous cell carcinoma, the eighth China approval for tislelizumab. In early 2021, BeiGene out-licensed global tislelizumab rights (ex-China) to Novartis in a $2.2 billion deal. Tislelizumab is designed to minimize binding to FcγR on macrophages. In pre-clinical studies, this binding lowers the anti-tumor activity of PD-1 antibodies by activating macrophage-mediated killing of T effector cells. More details....

Stock Symbols: (NSDQ: BGNE; HK: 06160; SHA: 688235)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital